- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05156385
Sexual Dysfunction in Hypertensive Women (DYSFHO)
Sexual Dysfunction in Hypertensive Women According to Drug Adherence: Multicenter Cross-sectional Study
Several studies describe the existence of an association between sexual dysfunction and high blood pressure (hypertension), most often characterized by a decrease in the number of orgasms and the existence of dyspareunia.
Hypertension is a contributing factor, and nonadherence to medication could amplify it.
There are several ways to assess adherence to treatment: the use of declarative questionnaires, a method not without criticism because it is subject to the subjectivity of the declaration by the patient; and drug dosages, a standard technique, although insufficiently disseminated due to the high cost and greater weight of the survey protocols. Drug non-compliance is multifactorial. In addition, it has been shown that having undesirable drug effects and / or being afraid of developing them is one of the major causes of non-compliance with antihypertensive treatments.
The investigators hypothesize that DS is significantly more common among hypertensive women treated with non-observers compared to hypertensive women treated with observers.
The main objective is to compare the prevalence of sexual dysfunction between a group of hypertensive women treated as observers and a group of hypertensive women treated as non-observers.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Delphine LAZARO-VERGE
- Phone Number: +33 5 61 32 30 68
- Email: lazaro.d@chu-toulouse.fr
Study Locations
-
-
CHU De Toulouse
-
Toulouse Cedex 9, CHU De Toulouse, France, 31059
- Recruiting
- LAZARO Delphine
-
Contact:
- Delphine LAZARO
- Phone Number: +33 5 61 32 30 68
- Email: lazaro.d@chu-toulouse.fr
-
Contact:
- Audrey TOMASIK
- Phone Number: +33 561778597
- Email: tomasik.a@chu-toulouse.fr
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Women over 18,
- Hospitalized or received in consultation for the management of hypertension treated in one of the hypertension and therapeutic, nephrology or cardiology departments participating in the study, with confirmed hypertension, treated with the following dosable antihypertensive agent(s): diltiazem, verapamil, acebutolol, atenolol, nébivolol, bisoprolol, metoprolol, propranolol, amiloride, furosemide, hydrochlorothiazide, indapamide, spironolactone, spironolactone, Lorsartan, Irbesartan, Ramipril, Perindopril, Amlodipine,
- Having signed the informed consent form.
- Beneficiary or affiliated to a French Social insurance
Exclusion Criteria:
- Patients with bariatric surgery,
- Patients under guardianship/trusteeship/protection of justice,
- Patients with diagnosed and treated psychosis or depression, - Pregnant or nursing women.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Hypertensive women
|
15 ml of Blood sample for the determination of antihypertensives or their metabolites
Questionnaire on sexual activity in women
Scale on hospital anxiety and depression to detect anxious and depressive symptoms (14 questions)
anti-hypertensive medication compliance questionnaire
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Analyse of sexual dysfunction
Time Frame: 25 months
|
Prevalence of sexual dysfunction defined by a score less than 26 on the Female Sexual Function Index scale : score less than 26 mean a sexual dysfunction
|
25 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of patients with a good medication compliance by drug dosages and the Morisky questionnaire
Time Frame: 25 months
|
Compare two methods of assessing drug compliance: drug dosages in the blood and the Morisky questionnaire; The score is rated on 8 points.
A score of 8 is considered "good observant", a score between 6 and 7 "moderately observant patient" and a score strictly lower than 6 "poor observant".
|
25 months
|
Number of cases with sexual dysfunction in hypertensive women according to the antihypertensive pharmacological classes used
Time Frame: 25 months
|
Estimate the prevalence of sexual dysfunction according to the antihypertensive pharmacological classes used (in the biologicale analysis)
|
25 months
|
Number of cases with sexual dysfunction in hypertensive women according to the number of antihypertensive treatments;
Time Frame: 25 months
|
Estimate the prevalence of sexual dysfunction according to the number of antihypertensive treatments;
|
25 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Delphine LAZARO-VERGE, MD, University Hospital, Toulouse
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- RC31/19/0553
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
BayerCompletedPrimary HypertensionChina
-
Columbia UniversityAgency for Healthcare Research and Quality (AHRQ)Active, not recruitingWhite Coat Hypertension | Hypertension,EssentialUnited States
-
Addpharma Inc.Completed
-
Universidade Federal de Santa MariaCompletedHealthy Volunteers | Hypertension, EssentialBrazil
-
Sheffield Teaching Hospitals NHS Foundation TrustUniversity of SheffieldCompletedIdiopathic Pulmonary Arterial Hypertension | Chronic Thromboembolic Pulmonary HypertensionUnited Kingdom
-
China Academy of Chinese Medical SciencesGuang'anmen Hospital of China Academy of Chinese Medical SciencesCompletedHypertension, Resistant to Conventional Therapy | Primary HypertensionChina
-
Cytos Biotechnology AGCompletedMild Essential Hypertension | Moderate Essential HypertensionSwitzerland
Clinical Trials on Blood sample for the determination of antihypertensives or their metabolites.
-
Petrovsky National Research Centre of SurgeryCompletedComplication | Aortic Aneurysm | Aortic Dissection | Thoracoabdominal AneurysmRussian Federation
-
University Hospital, AngersRecruitingDevelopment Delay | Cancer Childhood | Predisposition, GeneticFrance, Réunion
-
Massachusetts General HospitalJohns Hopkins University; M.D. Anderson Cancer Center; National Cancer Institute... and other collaboratorsRecruitingOvarian Neoplasms | Fallopian Tube Neoplasms | Stage III Ovarian Cancer AJCC v8 | Stage IIIA Ovarian Cancer AJCC v8 | Stage IIIA1 Ovarian Cancer AJCC v8 | Stage IIIA2 Ovarian Cancer AJCC v8 | Stage IIIB Ovarian Cancer AJCC v8 | Stage IIIC Ovarian Cancer AJCC v8 | Stage IV Ovarian Cancer AJCC v8 | Stage... and other conditionsUnited States
-
Hans SmitRijnstate Hospital; Prof. Dr. Jaap Swieringa stichting; Mr. Willem Bakhuys RoozeboomstichtingUnknown
-
University Hospital, ToursCompleted
-
University of MostarCompletedGestational DiabetesBosnia and Herzegovina
-
CHU de ReimsCompleted
-
Centre Leon BerardCentre de Recherche en Cancérologie de LyonCompletedBreast Cancer | MetastasisFrance
-
Felix GutierrezHospital Clinic of Barcelona; Hospital General Universitario Elche; Germans Trias... and other collaboratorsRecruiting
-
Universitat Jaume ICompleted